MDT

89.26

+1.81%↑

VEEV

230.09

-1.72%↓

A

116.25

-0.34%↓

HQY

86.75

-0.28%↓

PDCO

31.26

+0.1%↑

MDT

89.26

+1.81%↑

VEEV

230.09

-1.72%↓

A

116.25

-0.34%↓

HQY

86.75

-0.28%↓

PDCO

31.26

+0.1%↑

MDT

89.26

+1.81%↑

VEEV

230.09

-1.72%↓

A

116.25

-0.34%↓

HQY

86.75

-0.28%↓

PDCO

31.26

+0.1%↑

MDT

89.26

+1.81%↑

VEEV

230.09

-1.72%↓

A

116.25

-0.34%↓

HQY

86.75

-0.28%↓

PDCO

31.26

+0.1%↑

MDT

89.26

+1.81%↑

VEEV

230.09

-1.72%↓

A

116.25

-0.34%↓

HQY

86.75

-0.28%↓

PDCO

31.26

+0.1%↑

Search

AbbVie Inc

Avatud

SektorTervishoid

205.38 1.34

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

205.1

Max

206

Põhinäitajad

By Trading Economics

Sissetulek

-1.6B

-23M

Müük

642M

15B

P/E

Sektori keskmine

87.887

73.239

Aktsiakasum

2.16

Dividenditootlus

3.14

Kasumimarginaal

-0.152

Töötajad

55,000

EBITDA

-4.4B

535M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+5.01% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.14%

3.06%

Järgmine tulemuste avaldamine

25. apr 2025

Järgmine dividendimakse kuupäev

15. mai 2025

Järgmine aktsia dividendi kuupäev (ex-date)

15. apr 2025

Turustatistika

By TradingEconomics

Turukapital

35B

369B

Eelmine avamishind

204.04

Eelmine sulgemishind

205.38

Uudiste sentiment

By Acuity

51%

49%

291 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

AbbVie Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. veebr 2025, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

12. veebr 2025, 13:41 UTC

Suurimad hinnamuutused turgudel

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

31. jaan 2025, 13:28 UTC

Tulu

AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges

14. märts 2025, 09:30 UTC

Peamised uudised

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3. märts 2025, 15:04 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6. veebr 2025, 13:25 UTC

Peamised uudised
Tulu

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6. veebr 2025, 12:00 UTC

Tulu

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

5. veebr 2025, 12:00 UTC

Peamised uudised

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

31. jaan 2025, 15:50 UTC

Peamised uudised
Tulu

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31. jaan 2025, 13:51 UTC

Tulu

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate -- IBD

31. jaan 2025, 13:47 UTC

Peamised uudised
Tulu

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31. jaan 2025, 13:24 UTC

Market Talk
Tulu

AbbVie Gets More Upbeat on Skyrizi, Rinvoq -- Market Talk

31. jaan 2025, 12:46 UTC

Tulu

AbbVie's Stock Pops 4% After Earnings Beat Estimates And Company Offers Upbeat View Of 2025 -- MarketWatch

31. jaan 2025, 12:39 UTC

Tulu

AbbVie 4Q Global Rinvoq Net Revenue $1.83B, Up 46.2% >ABBV

31. jaan 2025, 12:38 UTC

Tulu

AbbVie: Expect 2025 Revenue to Exceed Previous Peak >ABBV

31. jaan 2025, 12:38 UTC

Tulu

AbbVie Now Sees Aesthetics Delivering High-Single-Digit Compound Annual Revenue Growth From 2025-2029 >ABBV

31. jaan 2025, 12:37 UTC

Tulu

AbbVie Raises 2027 Combined Sales Outlook for Skyrizi, Rinvoq to More Than $31B >ABBV

31. jaan 2025, 12:37 UTC

Tulu

AbbVie Reaffirms Expectations for High-Single-Digit Compound Annual Revenue Growth Rate Through 2029 >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie: 4Q Revenue Rose 6.1% on Operational Basis >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q Loss $22M >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q U.S. HUMIRA Rev $1.25B >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.69B >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q Global Skyrizi Rev $3.78B >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q International HUMIRA Rev $436M >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q Adj EPS $2.16 >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie Sees FY Adj EPS $12.12-Adj EPS $12.32 >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q Loss/Shr 2c >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q Global IMBRUVICA Rev $848M >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q Rev $15.1B >ABBV

Võrdlus sarnastega

Hinnamuutus

AbbVie Inc Prognoos

Hinnasiht

By TipRanks

5.01% tõus

12 kuu keskmine prognoos

Keskmine 215.57 USD  5.01%

Kõrge 240 USD

Madal 190 USD

Põhineb 16 Wall Streeti analüütiku instrumendi AbbVie Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

12

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

201.34 / 209.52Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Sentiment

By Acuity

291 / 386 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.